Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v40-v55.
Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328-2334.
Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:1641-1647.
Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg. 2005;130:1413-1421.
Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):357S-360S.
Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5(suppl 4):348S-351S.
1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and association with subsequent malignancies. Int J Cancer. 2003;105:546-551.
2. Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v40-v55.
3. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77:1860-1869.
4. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, eds. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1997:93-115.
5. Muller-Hermelink HK, Strobel P, Zetti A, et al. Combined thymic epithelial tumors. In: Travis WD, Brambilla E, Muller-Hermeling HK, eds. Pathology and genetics: tumors of the lung, pleura, thymus and heart (WHO classification of tumors). Lyon, France: IARC Press; 2004:196-201.
6. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328-2334.
7. Suadjian J, Enriquez P, Silverstein MN, et al. The spectrum of diseases associated with thymoma: coincidence or syndrome? Arch Intern Med. 1974;154:374-379.
8. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-1117.
9. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624-632.
10. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;75:878-885.
11. Filosso PL, Actis Dato GM, Ruffini E, et al. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg. 2004;127:1215-1219.
12. Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39:784-798.
13. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797-1810.
14. Wudel LJ, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001;2:77-91.
15. Marom EM. Imaging thymoma. J Thorac Oncol. 2010;5(suppl 4):296S-303S.
16. Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869-876.
17. Endo M, Nakagawa K, Ohde Y, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61:350-355.
18. Howard FM, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526-538.
19. Maher MM, Shepard JA. Imaging of thymoma. Semin Thorac Cardiovasc Surg. 2005;17:12-19.
20. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492.
21. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothorac Surg. 1994;8:251-253.
22. Masaoka A. Staging system of thymoma. J Thorac Oncol. 2010;5(suppl 4):304S-312S.
23. Falkson CB, Bezjak A, Darling G, et al; Cancer Care Ontario. The management of thymoma: a systematic review and practice guideline. July 2014. http://www.cancercare.on.ca (last accessed 15 September 2017).
24. Ettinger DS, Akerley W, Bepler G, et al; National Comprehensive Cancer Network. Thymic malignancies. J Natl Compr Canc Netw. 2010;8:1302-1315.
25. Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg. 2008;86:673-684.
26. Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002;74:1033-1037.
27. Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:1641-1647.
28. Giannopoulou A, Gkiozos I, Harrington KJ, et al. Thymoma and radiation therapy: a systematic review of medical treatment. Expert Rev Anticancer Ther. 2013;13:759-766.
29. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003;76:1866-1872.
30. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg. 2007;134:1477-1484.
31. Loehrer PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001;91:2010-2015.
32. Riely GJ, Huang J. Induction therapy for locally advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):323S-326S.
33. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg. 2008;85:385-389.
34. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093-3099.
35. Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology and size. J Thorac Cardiovasc Surg. 2005;130:1413-1421.
36. Huang J, Rizk NP, Travis WD. Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg. 2009;138:26-31.
37. Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010;5(suppl 4):357S-360S.
38. Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg. 2006;82:1234-1239.
39. Eng TY, Thomas CR. Radiation therapy in the management of thymic tumors. Semin Thorac Cardiovasc Surg. 2005;17:32-40.
40. Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol. 2010;5(suppl 4):348S-351S.
41. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893-902.
42. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789-796.
43. Qureshi AI, Choudry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629-632.
44. Kang SY, Lee JS, Choi JC, Kang JH. Myasthenia gravis appearing after thymectomy: a case report and review of the literature. J Clin Neurol. 2007;3:158-160.
45. Nations SP, Wolfe GI, Amato AA, et al. Myasthenia gravis developing after removal of a thymoma. J Child Neurol. 1997;2:133-135.
46. Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA. 2000;283:1142-1143.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台